Rosiglitazone Effect on Mitochondria and Lipoatrophy
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effect of rosiglitazone on limb fat and
mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that
does not contain stavudine (d4T) or zidovudine (AZT).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)